Overview of Short Wave from NPR: “Without this pill, lots of people would be dead”
This episode marks the 25th anniversary of Gleevec (imatinib), the cancer drug that helped launch the era of targeted cancer therapy. NPR’s Sydney Lupkin explains how Gleevec transformed chronic myeloid leukemia (CML) from a near-certain death sentence into a manageable, often long-term condition, using the story of patient Mel Mann and oncologist Brian Druker as the human and scientific center of the episode.
Why Gleevec Was a Breakthrough
Targeted treatment instead of broad chemotherapy
- Before Gleevec, cancer treatment often relied on toxic chemotherapy that attacked fast-growing cells broadly.
- Gleevec was designed to target the specific molecular abnormality driving a cancer, rather than just trying to kill as many cells as possible.
The science behind CML
- CML was one of the first cancers linked to a genetic abnormality: the Philadelphia chromosome.
- That mutation creates a fusion gene that produces an abnormal enzyme, which acts like a growth switch stuck in the “on” position.
- Gleevec works by blocking that enzyme, turning the switch off and stopping uncontrolled white blood cell growth.
Mel Mann’s Story: From Three Years to Live to a Normal Life
A devastating diagnosis
- Mel Mann was diagnosed with chronic myeloid leukemia in 1995 at age 37.
- Doctors told him he had about three years to live.
- He spent years trying to find a bone marrow transplant match, but as a Black patient, the odds were especially low at the time.
Experimental treatments and eventual recovery
- Before Gleevec, he joined clinical trials for other experimental drugs that only worked temporarily.
- By the time he started Gleevec in 1998, he was extremely fatigued and losing weight.
- Within months of treatment, his health dramatically improved.
- By the following year, he was running a marathon.
How Gleevec Was Developed
Brian Druker’s risky idea
- Oncologist Brian Druker believed cancer treatment should focus on the specific driver of a cancer, not just its symptoms.
- That idea was considered risky and unconventional at the time.
- He left Boston and moved to Oregon Health & Science University to pursue the work.
Fast-moving collaboration
- Druker tested compounds from the company that would become Novartis.
- One compound, Gleevec, worked in the lab and then in clinical trials.
- Unlike older cancer trials that lumped many cancer types together, Gleevec trials focused on patients with CML, since the drug was built for that specific disease.
Remarkable trial results
- Within six months, nearly every CML patient taking the effective dose responded to treatment.
- A Novartis biostatistician initially thought the survival data must be wrong because the results were so strong.
Approval and Broader Impact
Fast FDA approval
- Gleevec was approved on May 10, 2001.
- The FDA approval took only 72 days, unusually fast for the time.
A model of public-private cooperation
- The episode emphasizes that Gleevec’s success depended on:
- government-funded basic research,
- academic scientists willing to take risks,
- a pharmaceutical company funding trials,
- patients willing to enroll in experimental studies,
- and regulators moving quickly once the data were clear.
The start of a new era
- Gleevec helped usher in the modern era of targeted cancer drugs.
- There are now 100+ targeted cancer therapies on the market, many improving both survival and quality of life.
What Happened After Gleevec
Still in use today
- Gleevec remains in use, along with newer generations of related drugs.
- Some patients can even stop treatment and remain cancer-free.
Expanded uses
- Researchers later found Gleevec also helps treat certain gastrointestinal stromal tumors (GISTs) by blocking the same kind of uncontrolled growth pathway.
Human outcomes
- Mel Mann is now 69, has watched his daughter grow up, and even returned to school for another degree.
- Druker has seen former “terminal” patients live long enough for weddings, births, graduations, and grandchildren.
Key Takeaways
- Gleevec changed cancer medicine by proving that attacking a cancer’s specific molecular cause can work.
- It turned CML from a frequently fatal disease into one that many patients can manage long term.
- The story is also about scientific persistence, patient courage, and collaboration across academia, industry, government, and clinical care.
- Though it was once very expensive, Gleevec is now generic and far more affordable than when it launched.